Johnson Matthey PLC (LON:JMAT – Get Free Report) insider Liam Condon acquired 12 shares of the business’s stock in a transaction dated Friday, October 10th. The shares were bought at an average cost of GBX 2,079 per share, for a total transaction of £249.48.
Liam Condon also recently made the following trade(s):
- On Tuesday, August 12th, Liam Condon bought 14 shares of Johnson Matthey stock. The stock was bought at an average price of GBX 1,773 per share, with a total value of £248.22.
Johnson Matthey Price Performance
Shares of LON JMAT opened at GBX 2,156 on Thursday. The stock’s 50-day moving average is GBX 1,935.24 and its two-hundred day moving average is GBX 1,689.40. The company has a debt-to-equity ratio of 62.73, a current ratio of 1.45 and a quick ratio of 0.76. Johnson Matthey PLC has a 1-year low of GBX 1,131 and a 1-year high of GBX 2,188. The company has a market cap of £3.61 billion, a price-to-earnings ratio of 1,020.83, a price-to-earnings-growth ratio of 49,242.50 and a beta of 0.95.
Analysts Set New Price Targets
Get Our Latest Stock Report on Johnson Matthey
Johnson Matthey Company Profile
Johnson Matthey is a global leader in science that enables a cleaner and healthier world. With over 200 years of sustained commitment to innovation and technological breakthroughs, they improve the function, performance and safety of their customers’ products. Their science has a global impact in areas such as low emission transport, pharmaceuticals, chemical processing and making the most efficient use of the planet’s natural resources.
Further Reading
- Five stocks we like better than Johnson Matthey
- Value Investing: Is it a Good Strategy in 2022? (Hint: Always)
- Palantir’s New Healthcare Deal Boosts AI and Data Reach
- What is a Bond Market Holiday? How to Invest and Trade
- GM’s Billion-Dollar Bruise: GM’s Strategic Pivot Makes It a Buy
- Using the MarketBeat Dividend Tax Calculator
- Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead
Receive News & Ratings for Johnson Matthey Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson Matthey and related companies with MarketBeat.com's FREE daily email newsletter.